BR0314529A - Polipeptìdeos de papilomavìrus humano e composições imunogênicas - Google Patents
Polipeptìdeos de papilomavìrus humano e composições imunogênicasInfo
- Publication number
- BR0314529A BR0314529A BR0314529-8A BR0314529A BR0314529A BR 0314529 A BR0314529 A BR 0314529A BR 0314529 A BR0314529 A BR 0314529A BR 0314529 A BR0314529 A BR 0314529A
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic
- fusions
- immunogenic compositions
- hpv
- human papillomavirus
- Prior art date
Links
- 241000701806 Human papillomavirus Species 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000027450 oncoproteins Human genes 0.000 abstract 1
- 108091008819 oncoproteins Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41592902P | 2002-10-03 | 2002-10-03 | |
| PCT/US2003/031726 WO2004030636A2 (en) | 2002-10-03 | 2003-10-02 | Human papillomavirus polypeptides and immunogenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0314529A true BR0314529A (pt) | 2005-08-09 |
Family
ID=32069921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0314529-8A BR0314529A (pt) | 2002-10-03 | 2003-10-02 | Polipeptìdeos de papilomavìrus humano e composições imunogênicas |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7223408B2 (enExample) |
| EP (1) | EP1553966B1 (enExample) |
| JP (2) | JP4755422B2 (enExample) |
| KR (1) | KR101145190B1 (enExample) |
| CN (1) | CN1720060B (enExample) |
| AU (1) | AU2003282731B2 (enExample) |
| BR (1) | BR0314529A (enExample) |
| CA (1) | CA2499837C (enExample) |
| CO (1) | CO5700784A2 (enExample) |
| DK (1) | DK1553966T3 (enExample) |
| ES (1) | ES2391451T3 (enExample) |
| MX (1) | MXPA05003395A (enExample) |
| NZ (1) | NZ556544A (enExample) |
| PT (1) | PT1553966E (enExample) |
| WO (1) | WO2004030636A2 (enExample) |
| ZA (1) | ZA200502618B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
| EP1363938B1 (en) | 2000-08-03 | 2013-12-11 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
| CA2499837C (en) * | 2002-10-03 | 2013-12-03 | Wyeth Holdings Corporation | Human papillomavirus polypeptides and immunogenic compositions |
| EP1644048B1 (en) | 2003-05-05 | 2015-04-29 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
| US8399610B2 (en) * | 2004-08-05 | 2013-03-19 | University College Cardiff Consultants Limited | HPV vaccine comprising peptides from host cell proteins |
| GB0417430D0 (en) * | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| JP4474264B2 (ja) | 2004-08-20 | 2010-06-02 | 生寶生物科技股▲ふん▼有限公司 | 子宮頸癌抑制の融合蛋白 |
| ATE476528T1 (de) | 2004-12-08 | 2010-08-15 | Gen Probe Inc | Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus |
| WO2006073970A2 (en) | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines |
| JP2008526248A (ja) * | 2005-01-14 | 2008-07-24 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 生体試料におけるヒトパピローマウイルス検出のためのシステム、方法、および組成 |
| WO2006081323A2 (en) * | 2005-01-26 | 2006-08-03 | The Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin |
| US8137674B2 (en) | 2006-04-19 | 2012-03-20 | Postech Foundation | Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer |
| US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
| EP2162149B1 (en) * | 2007-06-01 | 2013-11-06 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccine for the prevention of breast cancer relapse |
| US20090117123A1 (en) * | 2007-11-02 | 2009-05-07 | National Health Research Institutes | Immunopeptides of hpv e6 and e7 proteins |
| US20120121715A1 (en) * | 2008-01-02 | 2012-05-17 | National Taiwan University | DNA Vaccine Comprising IL-6-Encoding DNA Construct and Applications Thereof |
| EP2335730A1 (en) * | 2009-12-18 | 2011-06-22 | Deutsches Krebsforschungszentrum | Fusion polypeptides and their use for prevention and treatment of cancer |
| KR101197627B1 (ko) * | 2010-01-18 | 2012-11-07 | (주)레퍼런스바이오랩 | Ｈｐｖ 감염과 관련된 암의 치료용 조성물 |
| CA2981303C (en) * | 2010-02-16 | 2020-06-30 | Becton, Dickinson And Company | Assay for detecting closely-related serotypes of human papillomavirus (hpv) |
| CA2799205A1 (en) | 2010-05-25 | 2011-12-01 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
| WO2012020871A1 (ko) * | 2010-08-13 | 2012-02-16 | 주식회사 제넥신 | 사람 파필로마바이러스 변형체 및 면역 증강제를 포함하는 자궁경부암 예방 또는 치료용 조성물 |
| KR102373828B1 (ko) * | 2011-10-12 | 2022-03-14 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법 |
| EP3533462A1 (en) * | 2011-12-21 | 2019-09-04 | Vaccibody AS | Vaccines against hpv |
| CN104159607A (zh) | 2012-01-24 | 2014-11-19 | 桑福德研究院/南达科他大学 | 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸 |
| CN103288931B (zh) * | 2012-02-24 | 2015-05-27 | 宋硕 | 人类乳头瘤病毒免疫原性多肽、其制备方法及应用 |
| WO2014165291A1 (en) | 2013-03-12 | 2014-10-09 | The Trustees Of The University Of Pennsylvania | Improved vaccines for human papilloma virus and methods for using the same |
| MX428954B (es) * | 2013-03-15 | 2025-11-13 | Univ Pennsylvania | Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana. |
| CN107073070A (zh) | 2014-08-15 | 2017-08-18 | 格纳西尼有限公司 | 治疗宫颈癌的方法 |
| JP5973007B2 (ja) * | 2015-01-30 | 2016-08-17 | ジェネクサイン・インコーポレーテッド | ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物 |
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| HK1246183A1 (zh) * | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| WO2017060360A1 (en) * | 2015-10-06 | 2017-04-13 | Invectys | Polyepitope constructs for use in immunotherapy |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| CN106632694B (zh) * | 2017-01-24 | 2021-02-12 | 南京益康生物医药有限公司 | 一种重组蛋白及药物组合物与应用 |
| CN110719788A (zh) * | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| EP3461497A1 (en) * | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| WO2021026335A1 (en) * | 2019-08-08 | 2021-02-11 | The Trustees Of Indiana University | Methods for identifying and treating urinary tract infections |
| WO2021205027A1 (en) | 2020-04-09 | 2021-10-14 | Vaccibody As | Individualized therapeutic anticancer vaccine |
| MX2022013063A (es) | 2020-04-24 | 2022-12-08 | Genexine Inc | Metodo para tratamiento del cancer cervicouterino. |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| CN114478712B (zh) * | 2022-03-29 | 2022-09-23 | 深圳吉诺因生物科技有限公司 | Hpv抗原表位及其鉴定方法、应用 |
| WO2024145863A1 (en) * | 2023-01-05 | 2024-07-11 | Virogin Biotech (Shanghai) Ltd. | A NOVEL mRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS |
| CN117925916A (zh) * | 2024-03-11 | 2024-04-26 | 广州市金域转化医学研究院有限公司 | Hpv dna的e6基因在制备浸润性宫颈癌诊断产品中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| AUPN015794A0 (en) * | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
| AUPN443995A0 (en) * | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| CN1433428A (zh) * | 2000-04-05 | 2003-07-30 | 冲击诊断公司 | 辨别人乳头瘤病毒的免疫学方法 |
| CA2499837C (en) * | 2002-10-03 | 2013-12-03 | Wyeth Holdings Corporation | Human papillomavirus polypeptides and immunogenic compositions |
-
2003
- 2003-10-02 CA CA2499837A patent/CA2499837C/en not_active Expired - Lifetime
- 2003-10-02 BR BR0314529-8A patent/BR0314529A/pt not_active Application Discontinuation
- 2003-10-02 NZ NZ556544A patent/NZ556544A/en unknown
- 2003-10-02 PT PT03774615T patent/PT1553966E/pt unknown
- 2003-10-02 AU AU2003282731A patent/AU2003282731B2/en not_active Expired
- 2003-10-02 EP EP03774615A patent/EP1553966B1/en not_active Expired - Lifetime
- 2003-10-02 US US10/530,253 patent/US7223408B2/en not_active Expired - Lifetime
- 2003-10-02 ES ES03774615T patent/ES2391451T3/es not_active Expired - Lifetime
- 2003-10-02 DK DK03774615.3T patent/DK1553966T3/da active
- 2003-10-02 CN CN200380104973XA patent/CN1720060B/zh not_active Expired - Lifetime
- 2003-10-02 JP JP2004541707A patent/JP4755422B2/ja not_active Expired - Lifetime
- 2003-10-02 KR KR1020057005780A patent/KR101145190B1/ko not_active Expired - Lifetime
- 2003-10-02 MX MXPA05003395A patent/MXPA05003395A/es active IP Right Grant
- 2003-10-02 WO PCT/US2003/031726 patent/WO2004030636A2/en not_active Ceased
-
2005
- 2005-03-31 ZA ZA200502618A patent/ZA200502618B/xx unknown
- 2005-04-28 CO CO05040563A patent/CO5700784A2/es unknown
-
2007
- 2007-01-26 US US11/627,697 patent/US7378099B2/en not_active Expired - Lifetime
-
2010
- 2010-08-13 JP JP2010181424A patent/JP5398665B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1553966A4 (en) | 2008-04-16 |
| WO2004030636A3 (en) | 2005-02-24 |
| US7223408B2 (en) | 2007-05-29 |
| CN1720060B (zh) | 2011-12-14 |
| ES2391451T3 (es) | 2012-11-26 |
| CA2499837C (en) | 2013-12-03 |
| JP2010279386A (ja) | 2010-12-16 |
| KR101145190B1 (ko) | 2012-05-14 |
| PT1553966E (pt) | 2012-10-22 |
| WO2004030636A2 (en) | 2004-04-15 |
| CO5700784A2 (es) | 2006-11-30 |
| US7378099B2 (en) | 2008-05-27 |
| EP1553966A2 (en) | 2005-07-20 |
| NZ556544A (en) | 2008-11-28 |
| MXPA05003395A (es) | 2005-06-22 |
| JP2006501825A (ja) | 2006-01-19 |
| JP5398665B2 (ja) | 2014-01-29 |
| KR20050053732A (ko) | 2005-06-08 |
| AU2003282731A1 (en) | 2004-04-23 |
| US20070275003A1 (en) | 2007-11-29 |
| CA2499837A1 (en) | 2004-04-15 |
| US20060014926A1 (en) | 2006-01-19 |
| ZA200502618B (en) | 2008-10-29 |
| DK1553966T3 (da) | 2012-09-17 |
| EP1553966B1 (en) | 2012-08-01 |
| AU2003282731B2 (en) | 2009-01-08 |
| CN1720060A (zh) | 2006-01-11 |
| JP4755422B2 (ja) | 2011-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004030636A3 (en) | Human papillomavirus polypeptides and immunogenic compositions | |
| MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
| BR0007840A (pt) | Proteìnas de fusão her-2/neu | |
| MXPA04001566A (es) | Un sistema para expresion y ensamblado de anticuerpos. | |
| EP2277889A3 (en) | Fusion proteins of albumin and interferon beta | |
| AU2002305450A1 (en) | Proteomimetic compounds and methods | |
| WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| PH12021550001A1 (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| AU3368497A (en) | Human dnase i hyperactive variants | |
| TNSN08064A1 (en) | Albumin fusion proteins | |
| WO2007092772A8 (en) | Protein formulations | |
| BR0207283A (pt) | Anticorpos anti-egfr modificados com imunogenicidade reduzida | |
| TW200507874A (en) | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use | |
| MX2009003729A (es) | Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a. | |
| WO2002012341A3 (en) | Her-2/neu fusion proteins | |
| BRPI0412845A (pt) | herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo | |
| NZ711567A (en) | Antibody formulations | |
| DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
| NO20064059L (no) | Albumin fusjonsproteiner | |
| BRPI0511751A (pt) | usos médicos de conjugados veìculos de peptìdeos de tnf não-humano | |
| WO2008093165A3 (en) | The use of pgil ohgosaccharyltransferase for o-glycosylating proteins | |
| AU2002356392A1 (en) | Bone polypeptide-1 | |
| BR0208041A (pt) | Interferon beta modificado com imunogenicidade reduzida | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| IL141984A0 (en) | Akt nucleic acids, polypeptides, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |